Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TRX-4 (TolerRx Inc).

William M Brown1

  • 1Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com

Idrugs : the Investigational Drugs Journal
|April 6, 2006
PubMed
Summary
This summary is machine-generated.

TRX-4, an anti-CD3 antibody, is being developed for type 1 diabetes and psoriasis. Phase II trials in type 1 diabetes are complete, with Phase III trials planned. Orphan Drug status was granted for recent-onset type 1 diabetes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Aortic Valve Replacement in Patient With Extensive Aortic Dissection: Role of "Balloon Flossing".

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Impact of low testing numbers on chronic wasting disease apparent prevalence.

Prion·2025
Same author

The Value and Challenges of an Ambulatory Intermediate Care Clinic: A Mixed-Methods Analysis.

The Journal of ambulatory care management·2025
Same author

Improved performance of nucleic acid-based assays for genetically diverse norovirus surveillance.

Applied and environmental microbiology·2023
Same author

Version or High Forceps, Which and When?

Buffalo medical journal·2023
Same author

The Impact of Variation in the Toll-like Receptor 3 Gene on Epizootic Hemorrhagic Disease in Illinois Wild White-Tailed Deer (<i>Odocoileus virginianus</i>).

Genes·2023

Area of Science:

  • Immunology
  • Endocrinology
  • Dermatology

Background:

  • TolerRx Inc. is developing TRX-4, a humanized monoclonal antibody targeting CD3.
  • TRX-4 is licensed from BTG plc.
  • The antibody is being investigated for autoimmune conditions.

Purpose of the Study:

  • To evaluate the potential of TRX-4 as a treatment for type 1 diabetes and psoriasis.
  • To advance TRX-4 through clinical trials for these indications.

Main Methods:

  • TRX-4 is a humanized monoclonal antibody.
  • Clinical trials are being conducted in patients with type 1 diabetes and psoriasis.
  • Phase II trials in type 1 diabetes have concluded.
  • Phase Ib clinical study enrollment is ongoing for psoriasis patients.

Related Experiment Videos

Main Results:

  • Phase II trials for type 1 diabetes have been completed.
  • TRX-4 has received Orphan Drug status for recent-onset type 1 diabetes.

Conclusions:

  • TRX-4 shows promise for treating type 1 diabetes and psoriasis.
  • Further clinical development, including a pivotal Phase III trial for type 1 diabetes, is planned.